Clinical trials: Advanced Digestive System Tumor
Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma
A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of BGB-B2033 alone or in combination with tislelizumab, with or without…
- Conditions
- Metastatic Hepatocellular Carcinoma, Local Advanced Hepatocellular Carcinoma, Alpha-fetoprotein (AFP)-Producing Gastric Cancer, Extragonadal Yolk Sac Tumors
- Trial name
- NCT06427941
- Testing
- BGB-B2033, Tislelizumab, Bevacizumab
- Where
- 51 sites in United States, Brazil and 7 more
- Volunteers
- 630 people
- Sponsor
- BeOne Medicines
Rectal Cancer
Preoperative Chemoradiotherapy Utilizing Intensity Modulated Radiation Therapy in Combination With Bevacizumab-FOLFOX
In this phase I trial neoadjuvant CCRT combining IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and BV-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens is planned for 15 locally advanced…
- Trial name
- NCT01395667
- Testing
- CCRT
- Where
- Taiwan
- Volunteers
- 15 people
- Sponsor
- National Taiwan University Hospital
Advanced Solid Tumor, Lymphoma
Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
Subjects who previously took part in the FT500-101 study and received allogeneic NK cell immunotherapy will take part in this long term follow-up study.
- Conditions
- Advanced Solid Tumor, Lymphoma, Gastric Cancer, Colorectal Cancer
- Trial name
- NCT04106167
- Testing
- Allogeneic natural killer (NK) cell
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Fate Therapeutics
Breast Cancer, Colon Cancer
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
Background: The p53 gene normally helps to stop cancer cells from growing. However, when the p53 gene is mutated or damaged, cancer cells may grow unchecked.
- Conditions
- Breast Cancer, Colon Cancer, Pancreatic Cancer, Sarcoma
- Trial name
- NCT01386502
- Testing
- p53: 264-272 peptide, CT-011
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Rectal Cancer
Capecitabine,Oxaliplatin & Erbitux Given Throughout Multi-Modal Therapy for Locally Advanced Rectal Adenocarcinoma
This is a phase II study of induction chemotherapy (capecitabine, oxaliplatin and cetuximab (erbitux)) followed by capecitabine, oxaliplatin, cetuximab and radiotherapy followed by surgery followed by adjuvant capecitabine…
- Trial name
- NCT00353457
- Testing
- Capecitabine, Oxaliplatin and Cetuximab, Radiation
- Volunteers
- 6 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
CPI-613 in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
This pilot clinical trial studies 6,8-bis(benzylthio)octanoic acid in treating patients with locally advanced or metastatic pancreatic cancer.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer
- Trial name
- NCT01839981
- Testing
- 6,8-bis(benzylthio)octanoic acid
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Rectal Cancer
Neoadjuvant Chemoradiation With RHUMAB VEGF (Avastin) for Rectal Cancer
Preoperative chemoradiation leads to increased pelvic control and overall survival, but both distant and local disease control remain problematic in locally advanced rectal cancer patients.
- Trial name
- NCT00113230
- Testing
- Avastin (Bevacizumab, RHUMAB VEGF), Capecitabine, Radiation Therapy
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Pancreatic Cancer
Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00006467
- Testing
- ISIS 2503, gemcitabine hydrochloride
- Where
- 16 sites in United States
- Volunteers
- 48 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
Bemarituzumab or Placebo Plus Chemotherapy in Gastric Cancers With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
The main objective of this study is to compare efficacy of bemarituzumab combined with oxaliplatin, leucovorin, and 5-fluorouracil (5-FU) (mFOLFOX6) to placebo plus mFOLFOX6 as assessed by overall survival (OS) in participants…
- Trial name
- FORTITUDE-101 (NCT05052801)
- Testing
- Bemarituzumab, mFOLFOX6
- Where
- 300 sites in United States, Argentina and 35 more
- Volunteers
- 547 people
- Sponsor
- Amgen
Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
The primary objective of this study was to assess the preliminary antitumor activity as indicated by overall response rate (ORR) of tislelizumab in combination with lenvatinib in participants with unresectable locally advanced or…
- Conditions
- Hepatocellular Carcinoma, Unresectable Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT04401800
- Testing
- Lenvatinib, Tislelizumab
- Where
- 9 sites in China
- Volunteers
- 64 people
- Sponsor
- BeiGene
Pancreatic Cancer
Phase I TH-302 Plus Gemcitabine Plus Nab-Paclitaxel in Pancreatic Cancer
This is a multicenter, open-label, Phase 1, dose escalation trial to evaluate the safety, tolerability, and recommended Phase 2 dose (RP2D) of TH-302 in combination with gemcitabine and nab-paclitaxel in previously untreated…
- Trial name
- NCT02047500
- Testing
- TH-302, Nab-paclitaxel, Gemcitabine
- Where
- 5 sites in United States
- Volunteers
- 19 people
- Sponsor
- ImmunoGenesis
Locally Advanced Cancer, Metastatic Cancer
Identification of In-hospital Patients in Need of Palliative Care Using a New Simplified Screening Tool
Every day many patients affected by chronic life-limiting illnesses are admitted into Internal Medicine wards, coming from the Emergency Department.
- Conditions
- Locally Advanced Cancer, Metastatic Cancer, Chronic Respiratory Failure, Chronic Heart Failure
- Trial name
- SST2017 (NCT04143230)
- Testing
- Screening for PC by means of two different screening tools
- Where
- Italy
- Volunteers
- 660 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Pancreas Neoplasms
Docetaxel Plus Oxaliplatin as Therapy in Patients With Pancreatic Cancer
The purpose of this study is to test a combination-therapy of oxaliplatin and docetaxel in patients with metastatic or locally advanced adenocarcinoma of the pancreas after failure of a palliative first line therapy.
- Trial name
- NCT00690300
- Testing
- Docetaxel, Oxaliplatin
- Where
- 5 sites in Germany
- Volunteers
- 44 people
- Sponsor
- University of Ulm
Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
Study of SBP-101 in Pancreatic Cancer
This phase 1 first-in-human study evaluates safety and tolerability of SBP-101 in subjects with previously treated pancreatic ductal adenocarcinoma and will identify the maximum tolerated dose (MTD).
- Trial name
- NCT02657330
- Testing
- SBP-101
- Where
- 4 sites in United States, Australia
- Volunteers
- 29 people
- Sponsor
- Panbela Therapeutics, Inc.
Oesophageal Squamous Cell Carcinoma, Gastric Cancer
A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)
The study is a phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participants aged 18 years…
- Conditions
- Oesophageal Squamous Cell Carcinoma, Gastric Cancer, Hepatocellular Carcinoma, Colorectal Cancer
- Trial name
- NCT05104567
- Testing
- THOR-707, Pembrolizumab, Cetuximab
- Where
- 29 sites in United States, Belgium and 7 more
- Volunteers
- 138 people
- Sponsor
- Sanofi
Colorectal Cancer
Cetuximab and Simvastatin in Treating Patients With Advanced or Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as cetuximab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT01190462
- Testing
- cetuximab, simvastatin, laboratory biomarker analysis
- Where
- 2 sites in Netherlands
- Volunteers
- 51 people
- Sponsor
- Leiden University Medical Center
HepatoCellular Carcinoma
Study of Y90-Radioembolization With Nivolumab in Asians With Hepatocellular Carcinoma
The purpose of this study is to evaluate the effect of liver-localised radioembolization and nivolumab on liver cancer.
- Trial name
- NCT03033446
- Testing
- Y-90 Radioembolization, Nivolumab
- Where
- Singapore
- Volunteers
- 40 people
- Sponsor
- National Cancer Centre, Singapore
Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
This phase I trial tests the safety, side effects, and best dose of calaspargase pegol-mknl in combination with cobimetinib in treating patients with pancreatic cancer that has spread to nearby tissue or lymph nodes (locally…
- Conditions
- Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage IIA Pancreatic Cancer AJCC v8
- Trial name
- NCT05034627
- Testing
- Biopsy, Calaspargase Pegol-mknl, Cobimetinib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- OHSU Knight Cancer Institute
Gastric Cancer
Enriched-CRT 2017: Advanced Gastric Cancer With LN+ and LVI+, Chemotherapy vs. Chemoradiotherapy
This Enriched-CRT 2017 trial is a prospective, multicenter trial for adjuvant chemoradiotherapy (CRT) and chemotherapy (CT) in radical resected advanced gastric cancer (GC) patients with lymph node metastasis (LN+) and…
- Trial name
- NCT03680261
- Testing
- chemoradiotherapy, chemotherapy
- Where
- China
- Volunteers
- 556 people
- Sponsor
- Shanghai Zhongshan Hospital
Locally Advanced Rectal Cancer, Electrochemotherapy
Endoscopic Assisted Electrochemotherapy in Addition to Neoadjuvant Treatment of Locally Advanced Rectal Cancer
The purpose of this study is to evaluate the efficacy and safety of neoadjuvant electrochemotherapy on locally advanced rectal cancer (UICC II-III) in an intended curative clinical setting, using an endoscopic electroporation…
- Conditions
- Locally Advanced Rectal Cancer, Electrochemotherapy, Neoadjuvant Therapy, Down Staging
- Trial name
- nECT (NCT03040180)
- Testing
- Electrochemotherapy with bleomycin, EndoVE
- Where
- 2 sites in Denmark
- Volunteers
- 40 people
- Sponsor
- Zealand University Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.